Cargando…

Pomalidomide combinations are a safe and effective option after daratumumab failure

PURPOSE: Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients’ population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients. METHODS: We performed a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brioli, Annamaria, Gengenbach, Laura, Mancuso, Katia, Binder, Mascha, Ernst, Thomas, Heidel, Florian H., Stauch, Thomas, Zamagni, Elena, Hilgendorf, Inken, Hochhaus, Andreas, Engelhardt, Monika, von Lilienfeld-Toal, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356885/ https://www.ncbi.nlm.nih.gov/pubmed/36781500 http://dx.doi.org/10.1007/s00432-023-04637-x

Ejemplares similares

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.
por: Brioli, Annamaria, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
por: Vaxman, I., et al.
Publicado: (2022)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
por: Kuan, Jew Win, et al.
Publicado: (2022)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation
por: Pulewka, Kristin, et al.
Publicado: (2020)

Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
por: He, Jianming, et al.
Publicado: (2022)

Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study
por: Rachow, Tobias, et al.
Publicado: (2020)

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
por: Crodel, Carl C., et al.
Publicado: (2020)

PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
por: Decimoni, Tassia Cristina, et al.
Publicado: (2023)

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
por: Montefusco, V., et al.
Publicado: (2023)

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
por: O’Hagan Henderson, Samantha, et al.
Publicado: (2021)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Case report: false positive elevated serum‐galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements
por: Rachow, Tobias, et al.
Publicado: (2016)

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
por: Voigt, Margarete, et al.
Publicado: (2021)

P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL
por: Montefusco, Vittorio, et al.
Publicado: (2023)

Psychosocial distress in young adults surviving hematological malignancies: a pilot study
por: Wittwer, Andreas, et al.
Publicado: (2022)

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
por: Frietsch, Jochen J, et al.
Publicado: (2019)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
por: Stegelmann, F., et al.
Publicado: (2022)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Sozioökonomische Benachteiligung als Risikofaktor für Krebserkrankungen – „closing the care gap“
por: Berger, Johannes, et al.
Publicado: (2022)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
por: Frietsch, Jochen J., et al.
Publicado: (2022)

Isolation of Hafnia paralvei co-harbouring bla(NDM-1) and bla(VIM-1) in a woman who underwent allogeneic hematopoietic stem cell transplantation
por: Appel, Tobias Manuel, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
por: Heidel, F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9q8segpqi7siq4ujhv1k2ga0n3